Canagliflozin Inhibited the Activity of Hemolysin and Reduced the Inflammatory Response Caused by <i<Streptococcus suis</i<
Highly virulent <i<Streptococcus suis</i< (<i<S. suis</i<) infections can cause Streptococcal toxic shock-like syndrome (STSLS) in pigs and humans, in which an excessive inflammatory response causes severe damage. Hemolysin (SLY) is a major virulence factor of <i<S. suis</i< serotype 2 that produces pores in the target cell membrane, leading to cytoplasmic K<sup<+</sup< efflux and activation of the NLRP3 inflammasome, ultimately causing STSLS. The critical aspect of hemolysin in the pathogenesis of <i<S. suis</i< type 2 makes it an attractive target for the development of innovative anti-virulence drugs. Here, we use the <i<S. suis</i< toxin protein (SLY) as a target for virtual screening. A compound called canagliflozin, a hypoglycemic agent, was identified through screening. Canagliflozin significantly inhibits the hemolytic activity of hemolysin. The results combined with molecular dynamics simulation, surface plasmon resonance, and nano differential scanning fluorimetry show that canagliflozin inhibits the hemolytic activity of SLY by binding to SLY. In addition, canagliflozin markedly reduced the release of SC19-induced inflammatory factors at the cellular level and in mice. Importantly, the combination of canagliflozin and ampicillin had a 90% success rate in mice, significantly greater than the therapeutic effect of ampicillin. The findings suggest that canagliflozin may be a promising new drug candidate for <i<S. suis</i< infections..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
International Journal of Molecular Sciences - 24(2023), 17, p 13074 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xiaodan Li [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|
|---|
| doi: |
10.3390/ijms241713074 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ093514794 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ093514794 | ||
| 003 | DE-627 | ||
| 005 | 20240413012204.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms241713074 |2 doi | |
| 035 | |a (DE-627)DOAJ093514794 | ||
| 035 | |a (DE-599)DOAJ89b9e98001fa44368c59789efaf89c47 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QH301-705.5 | |
| 050 | 0 | |a QD1-999 | |
| 100 | 0 | |a Xiaodan Li |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Canagliflozin Inhibited the Activity of Hemolysin and Reduced the Inflammatory Response Caused by <i<Streptococcus suis</i< |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Highly virulent <i<Streptococcus suis</i< (<i<S. suis</i<) infections can cause Streptococcal toxic shock-like syndrome (STSLS) in pigs and humans, in which an excessive inflammatory response causes severe damage. Hemolysin (SLY) is a major virulence factor of <i<S. suis</i< serotype 2 that produces pores in the target cell membrane, leading to cytoplasmic K<sup<+</sup< efflux and activation of the NLRP3 inflammasome, ultimately causing STSLS. The critical aspect of hemolysin in the pathogenesis of <i<S. suis</i< type 2 makes it an attractive target for the development of innovative anti-virulence drugs. Here, we use the <i<S. suis</i< toxin protein (SLY) as a target for virtual screening. A compound called canagliflozin, a hypoglycemic agent, was identified through screening. Canagliflozin significantly inhibits the hemolytic activity of hemolysin. The results combined with molecular dynamics simulation, surface plasmon resonance, and nano differential scanning fluorimetry show that canagliflozin inhibits the hemolytic activity of SLY by binding to SLY. In addition, canagliflozin markedly reduced the release of SC19-induced inflammatory factors at the cellular level and in mice. Importantly, the combination of canagliflozin and ampicillin had a 90% success rate in mice, significantly greater than the therapeutic effect of ampicillin. The findings suggest that canagliflozin may be a promising new drug candidate for <i<S. suis</i< infections. | ||
| 650 | 4 | |a <i<Streptococcus suis</i< | |
| 650 | 4 | |a hemolysin | |
| 650 | 4 | |a canagliflozin | |
| 650 | 4 | |a anti-hemolysin | |
| 653 | 0 | |a Biology (General) | |
| 653 | 0 | |a Chemistry | |
| 700 | 0 | |a Qingyuan Li |e verfasserin |4 aut | |
| 700 | 0 | |a Zhaoran Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Chenchen Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Xinyu Huo |e verfasserin |4 aut | |
| 700 | 0 | |a Hongjiang Lai |e verfasserin |4 aut | |
| 700 | 0 | |a Hao Lu |e verfasserin |4 aut | |
| 700 | 0 | |a Wenjia Lu |e verfasserin |4 aut | |
| 700 | 0 | |a Yulin Qian |e verfasserin |4 aut | |
| 700 | 0 | |a Wenqi Dong |e verfasserin |4 aut | |
| 700 | 0 | |a Chen Tan |e verfasserin |4 aut | |
| 700 | 0 | |a Manli Liu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Molecular Sciences |d MDPI AG, 2003 |g 24(2023), 17, p 13074 |w (DE-627)DOAJ00014584X |x 14220067 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:17, p 13074 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/ijms241713074 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/89b9e98001fa44368c59789efaf89c47 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/1422-0067/24/17/13074 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1661-6596 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1422-0067 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 17, p 13074 | ||